A simple method to purify recombinant HCV core protein expressed in Pichia pastoris for obtaining virus-like particles and producing monoclonal antibodies

Pechelyulko, A. A.; Andreeva-Kovalevskaya, Zhanna I.; Dmitriev, D. A.; Лавров, В. Ф.; Massino, Y; Nagel, Alexey; Segal, O.L.; Sokolova, Olga; Solonin, Alexander S.; Tarakanova, Yu. N.; Дмитриев, А. Д.

doi:10.1016/j.pep.2021.105864

Cited by 7 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, VLPs composed of different viral proteins have successfully been produced in S. cerevisiae and P. pastoris (Table 4). ORF2, aa 112-608 [90] ORF2, aa 112-607 (HEV genotype IV) [122] Hepatitis B virus -Surface protein (HBsAg) [123,124] -Viral M [preS2 + S] [125] -Wild-type and mutant C69R S genes [126] -Surface protein (HBsAg) [115,[127][128][129] -Core protein (HBc) [130,131] -26 amino acids of PreS2 C-terminus (aa 120-145) [114] Hepatitis C virus -Core protein (HBc) [132,133] -CoreE1E2 protein, which consists of Core (269 nt-841nt) E1 (842 nt-1417nt), and E2 (1418 nt-2506nt) [134][135][136][137][138] E2 Core Domain [111] HPV 16,11,6,58 Human papillomavirus major capsid protein L1 [139][140][141][142][143][144] -Human papillomavirus major capsid protein L1 [85,86,[145][146][147][148][149] Coxsackievirus Capsid protein precursor P1 and the protease 3CD of Coxsackievirus A16 [150] -Capsid protein precursor P1 and the protease 3CD Coxsackievirus A16 [74,151] -Capsid protein precursor P1 and the protease 3CD of Coxsackievir...…”

Section: Comparison Of Vlp Production In the Three Yeast Speciesmentioning

confidence: 99%

Yeast and Virus-like Particles: A Perfect or Imperfect Couple?

Brachelente,

Galli,

Cervelli

2023

Applied Microbiology

View full text Add to dashboard Cite

Virus-like particles (VLPs) comprise viral structural proteins that self-assemble to form a particle similar to the native virus capsid. Since their discovery, they have been employed mainly as vaccines to prevent viral infection because they can elicit an immune response. Besides their use as vaccines, their application in cancer prevention and drug delivery is under intensive investigation. They can be produced in different systems such as bacteria, mammalian, plant, insect, and yeast cells. The main hurdle for their use is establishing a platform for production because many variables need to be considered. First, VLPs must be effective in the action for which they are constructed, depending on the nature of the VLPs. Second, the production platform must be suitable for safe and high-scale production. Yeast has been shown to be a valuable tool in VLP production, as it is able to express heterologous proteins efficiently and its manipulation is cheap and easy. Several species have been employed for this purpose. In the present review, we analyze the features of different yeast species and how they have been used to produce VLPs.

show abstract

Section: Comparison Of Vlp Production In the Three Yeast Speciesmentioning

confidence: 99%

Yeast and Virus-like Particles: A Perfect or Imperfect Couple?

Brachelente,

Galli,

Cervelli

2023

Applied Microbiology

View full text Add to dashboard Cite

show abstract

“…The vaccine protein, especially the envelope glycoprotein, is mainly expressed intracellularly and is insoluble through the addition of the signal peptide sequence during recombinant expression ( 71 ). It is generally believed that the strong hydrophobicity of the C-terminus of the E2 protein is the main reason for this ( 75 , 76 ).…”

Section: Difficulties In Vaccine Preparationmentioning

confidence: 99%

Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review)

Zhao

Zhang

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a global health challenge, and prophylactic vaccines are the most effective way to eliminate the infection. To date, numerous forms of preventive vaccines have entered the clinical trial stage, including the virus-like particle (VLP) vaccine, recombinant subunit vaccine, peptide vaccine and nucleic acid vaccine. The rational design makes it easier to obtain specific vaccine structures with a broad spectrum and strong immunogenicity. Different vaccine antigens can evoke different immune responses, including humoral and T-cell immune responses, and can be produced using different expression systems, such as bacteria, yeast, mammals, plants, insects or parasites. Intracellular and insoluble production and a narrow immune spectrum are two difficulties that limit the application of vaccines. The present study summarizes the immunogenicity of different preventive vaccines, evaluates the characteristics of different expression systems used for vaccine production, and analyzes the strategies to enhance the secretion and immune spectrum of vaccine proteins.

show abstract

Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches

Rzymski,

Jibril,

Rahmah

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Despite remarkable progress in the treatment of hepatitis C virus (HCV) infection, it remains a significant global health burden, necessitating the development of an effective prophylactic vaccine. This review paper presents the current landscape of HCV vaccine candidates and approaches, including more traditional, based on inactivated virus, and more modern, such as subunit protein, vectored, based on nucleic acids (DNA and mRNA) and virus‐like particles. The concept of the HCV vaccine is first put in the context of viral genetic diversity and adaptive responses to HCV infection, an understanding of which is crucial in guiding the development of an effective vaccine against such a complex virus. Because ethical dimensions are also significant in vaccine research, development, and potential deployment, we also address them in this paper. The road to a safe and effective vaccine to prevent HCV infection remains bumpy due to the genetic variation of HCV and its ability to evade immune responses. The progress in cell‐culture systems allowed for the production of an inactivated HCV vaccine candidate, which can induce cross‐neutralizing antibodies in vitro, but whether this could prevent infection in humans is unknown. Subunit protein vaccine candidates that entered clinical trials elicited HCV‐specific humoral and cellular responses, though it remains to be shown whether they translate into effective prevention of HCV infection or progression of infection to a chronic state. Such responses were also induced by a clinically tested vector‐based vaccine candidate, which decreased the viral HCV load but did not prevent chronic HCV infection. These disappointments were not readily predicted from preclinical animal studies. The vaccine platforms employing virus‐like particles, DNA, and mRNA provide opportunities for the HCV vaccine, but their potential in this context has yet to be shown. Ensuring the designed vaccine is based on conserved epitope(s) and elicits broadly neutralizing immune responses is also essential. Given failures in developing a prophylactic HCV vaccine, it is crucial to continue supporting national strategies, including funding for screening and treatment programs. However, these actions are likely insufficient to permanently control the HCV burden, encouraging further mobilization of significant resources for HCV vaccine research as a missing element in the elimination of viral hepatitis as a global public health.

show abstract

A simple method to purify recombinant HCV core protein expressed in Pichia pastoris for obtaining virus-like particles and producing monoclonal antibodies

Cited by 7 publications

References 24 publications

Yeast and Virus-like Particles: A Perfect or Imperfect Couple?

Yeast and Virus-like Particles: A Perfect or Imperfect Couple?

Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review)

Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches

Contact Info

Product

Resources

About